Other Events ·
Curanex faces second securities class action over August 2025 IPO
CURXCuranex Pharmaceuticals Inc
On September 14, 2026, Robert Lovett filed a putative securities class action against Curanex Pharmaceuticals Inc., its former CFO, directors, auditor, and underwriters. This follows a July 23, 2026 filing by Daymond Morales. Both suits allege material misstatements in the August 2025 IPO offering documents regarding stock-price manipulation risks and underwriter due diligence deficiencies. Claims are brought under Sections 11 and 12(a)(2) of the Securities Act. The company intends to defend vigorously, with response deadlines extended to November 15, 2026, and December 11, 2026, respectively. Curanex Pharmaceuticals Inc operates in the biopharmaceutical industry.